Arpita Desai

机构：University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center

发表论文 86 篇 · 总被引 2674 次 · h-index 18

代表论文

• Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology (2022 · Journal of the National Comprehensive Cancer Network · 被引 676)
• Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2022 · The Lancet Oncology · 被引 296)
• NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024 (2024 · Journal of the National Comprehensive Cancer Network · 被引 189)
• Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial (2023 · The Lancet Oncology · 被引 102)
• Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma (2023 · Cancer Drug Resistance · 被引 37)
• TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor (2021 · Journal for ImmunoTherapy of Cancer · 被引 33)